Share this article
Share this article
CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ PAQ Therapeutics, a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, today announced the completion of its $30 million Series A financing. PAQ s approach and technology expands the therapeutic potential of autophagy - the body s most versatile mechanism for natural cellular degradation – to target not only disease-causing proteins but lipids, pathogens and other substrates with the goal of restoring health. Sherpa Healthcare Partners led the Series A financing with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund, joined by seed investors, Nest.Bio Ventures and Matrix Partners China.
China
Huagai
Sichuan
Shanghai
Cambridge
Cambridgeshire
United-kingdom
Massachusetts
United-states
Cheng-xing
Jiangsu
Dee-glen